学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动

2020-05-12 神外前沿 神外前沿

我国原研新药ACT001通过靶向抑制转录因子STAT3的磷酸化而抑制免疫检查点分子PD-L1的转录表达,能够抑制小鼠模型中GBM的生长并延长荷瘤鼠的生存期。

近日,天津医科大学总医院神经外科杨学军教授团队联合美国约翰霍普金斯大学医学院神经外科Michael Lim教授团队及南开大学ACT001原研团队成员等在生物医学1区杂志《Theranostics》(2018 IF: 8.063)上发表论文,报道了我国原研新药ACT001通过靶向抑制转录因子STAT3的磷酸化而抑制免疫检查点分子PD-L1的转录表达,能够抑制小鼠模型中GBM的生长并延长荷瘤鼠的生存期,有望向临床转化。

天津医科大学总医院神经外科杨学军教授为文章的通讯作者,课题组成员童鹿青博士(联合培养)和李佳博博士为文章的并列第一作者。

据神外前沿了解,原研新药ACT001在国内的II期临床试验,也将很快启动,并由天津医科大学总医院神经外科的杨学军教授担任总负责人。

原文链接:https://www.thno.org/v10p5943.htm

据了解,脑胶质母细胞瘤(glioblastoma,GBM)本身就具有相当的免疫抑制特点,而现行放化疗在有限地提高患者生存时间的同时还促进了GBM的免疫抑制。因难以通过血脑屏障等局限性,PD-1单抗等在其他肿瘤中能够显著逆转肿瘤免疫抑制的药物,均折戟于GBM的Ⅲ期临床试验。因此,逆转脑GBM免疫抑制的药物亟待开发。

ACT001是中国南开大学药学院陈悦教授团队研发的抗肿瘤新药,保留了PTL的药物活性基团,但又克服了PTL不稳定、水溶性差的缺点。目前,ACT001针对复发GBM的Ⅱ期临床试验,先后获得美国FDA与中国药监局的许可。

在此项研究中,研究人员发现STAT3分子在GBM治疗抵抗和免疫抑制中扮演重要角色。ACT001能够抑制GBM细胞STAT3磷酸化和PD-L1的表达。深入研究后发现磷酸化的STAT3能够结合到PD-L1的启动子上从而促进PD-L1的转录;ACT001恰好能够靶向结合STAT3并抑制其磷酸化。免疫健全的小鼠原位脑GBM模型进一步证实,口服400mg/kg/d的ACT001可显著抑制脑GBM中p-STAT3和PD-L1的表达,并显著延长荷瘤鼠的生存期。

该研究在体内外实验中证明了ACT001能够靶向抑制p-STAT3和PD-L1的表达从而逆转脑GBM的免疫抑制状态。鉴于脑GBM是具有显著异质性的疾病,这一结果提示p-STAT3高表达患者可能从ACT001治疗中获益。另外,ACT001与现行的GBM放化疗联合应用可能可以抵消放化疗产生的免疫抑制,从而产生协同作用。

参考文献:

Tong L, Li J, Li Q, Wang X, Medikonda R, Zhao T, Li T, Ma H, Yi L,Liu P, Xie Y, Choi J, Yu S, Lin Y, Dong J, Huang Q, Jin X, Lim M, Yang X. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics 2020; 10(13):5943-5956. doi:10.7150/thno.41498.

论文通讯作者

 

杨学军 教授,医学博士,主任医师,教授,博士生导师,从事神经外科学医疗、教学及科研工作29年,主要专业方向为神经系统肿瘤的临床诊治与研究,现任天津医科大学总医院神经外科副主任,神经外科教研室主任,脑肿瘤与脑功能病区主任,天津市神经病学研究所研究室主任及临床PI,国家神经系统疾病临床研究中心授牌“全球脑胶质瘤适应性临床创新试验中国中心”主任;学术任职:WFNS会员,欧亚神经外科学院(Euroasian Neurosurgical Academy)执行委员兼秘书,中国医师协会胶质瘤专业委员会副主任委员,中国脑胶质瘤协作组组长、京津冀(晋蒙)胶质瘤诊疗联盟主任委员、北京肿瘤学会神经肿瘤专委会主任委员等,《中国现代神经疾病杂志》及《Glioma》副主编及其他十余种专业杂志编委或审稿专家;卫生部科技进步二等奖、天津市科技进步一等奖、二等奖、天津市青年科技奖、天津市十一五特殊贡献奖获奖者;天津市“科技传播之星”;天津医科大学科技精英及跨世纪与新世纪学术带头人;2016年度王忠诚中国神经外科医师学术成就奖获奖者;首届“中国医师节”天津医科大学“临床教学贡献奖”;主持国家重点研发专项、国家自然科学基金及省部级课题10余项,发表中英文论文180多篇,参编专著近30余部,参加9部神经外科领域的指南或共识编写。

论文第一作者

 

童鹿青,医学博士,外科学(神经外科)专业,方向为脑胶质瘤研究。天津医科大学2015级硕博连读,2018.10-2020.06国家公派美国约翰霍普金斯大学医学院联合培养博士。从事脑胶质瘤的免疫相关预后标志物及ACT001抗胶质瘤机制研究。硕博士期间曾担任党支部书记、团支部书记等职务,多次获得天津医科大学优秀研究生、优秀共青团员及优秀共产党员等荣誉。以第一或共同第一作者发表SCI论文5篇,累计影响因子19.6分,申报实用新型专利1项,参与译注1部。

论文第一作者

 

李佳博,天津医科大学2019级博士研究生,外科学(神经外科)专业,主要研究方向为脑胶质瘤。研究生期间致力于ACT001抗胶质瘤干细胞和免疫抑制性微环境的机制研究及脑胶质瘤的免疫相关预后标志物的研究。期间以第一或共同第一作者发表中英文论文4篇,其中SCI论文2篇;另外参与发表SCI论文7篇。作为主要参与者,参与多项国家自然科学基金面上项目、天津市科委重点项目、京津冀基础研究合作项目。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958269, encodeId=8353195826943, content=<a href='/topic/show?id=d46118945d' target=_blank style='color:#2F92EE;'>#ACT001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1894, encryptionId=d46118945d, topicName=ACT001)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jun 25 04:34:33 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931510, encodeId=14d7193151074, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 21 17:34:33 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923503, encodeId=9e0d1923503b4, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Feb 18 23:34:33 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653025, encodeId=384e165302564, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:34:33 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088803, encodeId=c3f32088803b8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 09 11:34:33 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524811, encodeId=ef2415248110f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu May 14 06:34:33 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039238, encodeId=3cdd103923831, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue May 12 18:34:33 CST 2020, time=2020-05-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958269, encodeId=8353195826943, content=<a href='/topic/show?id=d46118945d' target=_blank style='color:#2F92EE;'>#ACT001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1894, encryptionId=d46118945d, topicName=ACT001)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jun 25 04:34:33 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931510, encodeId=14d7193151074, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 21 17:34:33 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923503, encodeId=9e0d1923503b4, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Feb 18 23:34:33 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653025, encodeId=384e165302564, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:34:33 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088803, encodeId=c3f32088803b8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 09 11:34:33 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524811, encodeId=ef2415248110f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu May 14 06:34:33 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039238, encodeId=3cdd103923831, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue May 12 18:34:33 CST 2020, time=2020-05-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958269, encodeId=8353195826943, content=<a href='/topic/show?id=d46118945d' target=_blank style='color:#2F92EE;'>#ACT001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1894, encryptionId=d46118945d, topicName=ACT001)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jun 25 04:34:33 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931510, encodeId=14d7193151074, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 21 17:34:33 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923503, encodeId=9e0d1923503b4, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Feb 18 23:34:33 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653025, encodeId=384e165302564, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:34:33 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088803, encodeId=c3f32088803b8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 09 11:34:33 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524811, encodeId=ef2415248110f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu May 14 06:34:33 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039238, encodeId=3cdd103923831, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue May 12 18:34:33 CST 2020, time=2020-05-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958269, encodeId=8353195826943, content=<a href='/topic/show?id=d46118945d' target=_blank style='color:#2F92EE;'>#ACT001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1894, encryptionId=d46118945d, topicName=ACT001)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jun 25 04:34:33 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931510, encodeId=14d7193151074, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 21 17:34:33 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923503, encodeId=9e0d1923503b4, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Feb 18 23:34:33 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653025, encodeId=384e165302564, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:34:33 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088803, encodeId=c3f32088803b8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 09 11:34:33 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524811, encodeId=ef2415248110f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu May 14 06:34:33 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039238, encodeId=3cdd103923831, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue May 12 18:34:33 CST 2020, time=2020-05-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958269, encodeId=8353195826943, content=<a href='/topic/show?id=d46118945d' target=_blank style='color:#2F92EE;'>#ACT001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1894, encryptionId=d46118945d, topicName=ACT001)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jun 25 04:34:33 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931510, encodeId=14d7193151074, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 21 17:34:33 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923503, encodeId=9e0d1923503b4, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Feb 18 23:34:33 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653025, encodeId=384e165302564, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:34:33 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088803, encodeId=c3f32088803b8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 09 11:34:33 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524811, encodeId=ef2415248110f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu May 14 06:34:33 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039238, encodeId=3cdd103923831, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue May 12 18:34:33 CST 2020, time=2020-05-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1958269, encodeId=8353195826943, content=<a href='/topic/show?id=d46118945d' target=_blank style='color:#2F92EE;'>#ACT001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1894, encryptionId=d46118945d, topicName=ACT001)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jun 25 04:34:33 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931510, encodeId=14d7193151074, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 21 17:34:33 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923503, encodeId=9e0d1923503b4, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Feb 18 23:34:33 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653025, encodeId=384e165302564, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:34:33 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088803, encodeId=c3f32088803b8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 09 11:34:33 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524811, encodeId=ef2415248110f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu May 14 06:34:33 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039238, encodeId=3cdd103923831, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue May 12 18:34:33 CST 2020, time=2020-05-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1958269, encodeId=8353195826943, content=<a href='/topic/show?id=d46118945d' target=_blank style='color:#2F92EE;'>#ACT001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1894, encryptionId=d46118945d, topicName=ACT001)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jun 25 04:34:33 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931510, encodeId=14d7193151074, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 21 17:34:33 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923503, encodeId=9e0d1923503b4, content=<a href='/topic/show?id=ef2f52e50d4' target=_blank style='color:#2F92EE;'>#总医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52750, encryptionId=ef2f52e50d4, topicName=总医院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Feb 18 23:34:33 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653025, encodeId=384e165302564, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jun 14 11:34:33 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088803, encodeId=c3f32088803b8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 09 11:34:33 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524811, encodeId=ef2415248110f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu May 14 06:34:33 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039238, encodeId=3cdd103923831, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue May 12 18:34:33 CST 2020, time=2020-05-12, status=1, ipAttribution=)]
    2020-05-12 肿肿

    机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要

    0

相关资讯

盘点:2020年度Radiology科研进展汇总(六)

Radiology:或许这才是靠谱体脂率测量的方法!

ONC201治疗胶质瘤的I / II期临床研究即将在日本开展

Oncoceutics制药公司宣布,ONC201已在临床前模型和多项正在进行的临床试验中证明了其抗胶质瘤的有效性和安全性。

Angewandte Chemie:新型探针有助可视化检测胶质瘤标志物

日前,中国科学院院士黄维与南京工业大学教授李林团队、新加坡国立大学科研人员合作,设计合成了一种新的双光子荧光探针,这将有助于未来临床上对人源胶质瘤标志物(单胺氧化酶 A,即 MAO-A)进行可视化精准

疫路有我,阔然开朗:胶质瘤、脑转移瘤在线公益答疑

2020年3月14日,第一期“阔然专栏”在线直播栏目邀请复旦大学附属华山医院秦智勇教授、盛晓芳教授、梁晓华教授、庄冬晓教授和陈宏教授、徐州医科大学附属医院肿瘤中心章龙珍教授、复旦大学附属肿瘤医院曹依群

Nat Cell Bio:利用CRISPR技术精准修正胶质瘤致癌基因突变

研究人员使用腺相关病毒(Adeno-associated virus, AAV)作为载体表达拥有腺嘌呤脱氨酶活性的空肠弯曲菌(Campylobacter jejuni)Cas9融合蛋白以及对应的单向导RNA(sgRNA),实现精准修正胶质瘤细胞端粒酶基因启动子区域的致癌突变。

Radiology:IDH1突变胶质瘤在超高分辨率3D MR波谱下会有什么发现?

异柠檬酸脱氢酶(IDH)突变在胶质瘤中是非常常见的,会导致D- 2- 羟基戊二酸共代谢物(D-2HG)水平升高。因此,D-2HG水平可作为IDH突变胶质瘤非常有价值的影像学标记物。